WHITEHAWK THERAPEUTICS INC
WHWKNASDAQTrading Snapshot
- Day Range
- $3.72 – $3.80
- 52-Week Range
- $1.82 – $5.50
- Volume
- $1.90B
- Avg Volume
- $2.24B
- Shares Outstanding
- 57.0M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- -3.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.96
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +155.5%
Why Investors Own WHWK
- ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
WHITEHAWK THERAPEUTICS INC
WHWK
StockOtter · stockotter.spaceAbout WHITEHAWK THERAPEUTICS INC
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20
Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. On
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PR Newswire
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a c
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently devel
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.